PepGen总裁兼首席执行官James McArthur博士解释说，暂停CONNECT2是为了让公司专注于完成CONNECT1，并可能根据即将获得的数据优化CONNECT2研究设计。这一决定还旨在保留资源推进其在肌强直性营养不良1型 (DM1)中应用PGN-EDODM1的FREEDOM研究，该研究已显示出令人鼓舞的初步数据。 InvestingPro ...

Company will temporarily pause CONNECT2 and focus efforts on ongoing CONNECT1-EDO51 study of PGN-EDO51 in DMD, with 10 mg/kg results expected in the third quarter of 2025 No new safety issues have ...

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies ...

PepGen paused its Phase 2 CONNECT2 study of PGN-EDO51 in DMD to review 10 mg/kg cohort data from CONNECT1, expected in Q3 2025. No new safety concerns have emerged and the company aims to refine ...

No new safety issues related to PGN-EDO51 have been observed since the Company’s last safety update as of January 23, 2025. “With our 10 mg/kg cohort of CONNECT1 study fully enrolled and data ...

Recent Program Updates PGN-EDODM1: Myotonic Dystrophy Type 1 (DM1) PGN-EDO51: Duchenne Muscular Dystrophy (DMD) The 10 mg/kg cohort is fully enrolled (n=4) and participants in the 5 mg/kg cohort ...

NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of PepGen Inc.

Paul Streck, MD, Head of R&D, commented, “As of January 23, 2025, all treatment related adverse events in CONNECT1 have been mild, and we believe that the emerging safety profile of PGN-EDO51 ...